Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Annual Breast Cancer Examination Recommended for Patients on HRT
December 8, 2008
- BUSINESS NEWS IN BRIEF
December 8, 2008
- Children with SGA Short Stature Require Early Treatment: Pfizer Seminar
December 8, 2008
- MOF Proposes Carrot-and-Stick Approach to Encourage Insurers to Use More Generics
December 8, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 8, 2008
- Share of Generics Too Low: MOF Council
December 8, 2008
- CMIC Aims at Entry into Western Market to Become a Global CRO
December 1, 2008
- Irbesartan Fails to Improve Outcome of Heart Failure Patients with Preserved LVEF
December 1, 2008
- TOPICS／Number of MRs Decreases for First Time in 2007
December 1, 2008
- Subject Enrollment to a PIII Trial of AMG706 Stopped
December 1, 2008
- Combined Sales of TSE 1st Section-Listed 22 Pharmas Up 3.9%
December 1, 2008
- Standard Forms Adopted by Only 70% of Med Institutions Participating in Clinical Trials
December 1, 2008
- VITAL-NET, KSK to Merge to Create 5th Largest Drug Wholesaler
December 1, 2008
- R&D NEWS IN BRIEF
December 1, 2008
- Korosho to Press Large Hospitals to Settle Prices by Year-End
December 1, 2008
- Japan Needs NHI Pricing System That Encourages Innovation: Mr Kinoshita
December 1, 2008
- Advent of Wholesaler Behemoth Will Induce Power Shift
December 1, 2008
- REGULATORY NEWS IN BRIEF
December 1, 2008
- Matsumotokiyoshi to Provide Dispensing Services at 200 Stores
December 1, 2008
- JODA Introduces GL for Online Sales of OTC Drugs
December 1, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…